Cost-effectiveness of plasmapheresis and hemoperfusion in COVID-19 survivors: A six-month follow-up analysis after hospital discharge
Abstract
A six-month follow-up analysis examining the clinical outcomes and costs of plasmapheresis and hemoperfusion in patients who survived critical COVID-19, assessed after hospital discharge. The analysis found limited long-term cost-effectiveness for these extracorporeal therapies.
Type
Publication
Therapeutic Apheresis and Dialysis, 30(5): 769–781
Authors
Physician-Scientist & PhD Student | Biomedical Informatics & Data Science
Physician and Biomedical Informatics Ph.D. researcher at Arizona State University advancing computational cardiology, health wearables, and digital health systems. Combines clinical training and frontline primary care experience with machine learning, wearable biosignals, and cardiovascular physiological modeling. Research centers on anchoring continuous wearable sensor streams and clinical data in cardiovascular mechanics and physiological rationale, with a focus on cardio-oncology and evidence-grounded health data interoperability. Bridges the gap between physiological modeling and real-world clinical practice.